PARCIVAL
Partner Network for a Clinically Validated Multi-Analyte Lab-on-a-Chip Platform
| Coordinatore | ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Totale costo | 4˙132˙600 € |
| EC contributo | 2˙973˙550 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2011-two-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-01-01 - 2014-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
NL (ROTTERDAM) | coordinator | 353˙400.00 |
| 2 |
HAHN-SCHICKARD-GESELLSCHAFT FUER ANGEWANDTE FORSCHUNG E.v.
Organization address
address: WILHELM-SCHICKARD-STRASSE 10 contact info |
DE (Villingen) | participant | 553˙750.00 |
| 3 |
PATHOFINDER HOLDING BV
Organization address
address: RANDWYCKSINGEL 45 contact info |
NL (MAASTRICHT) | participant | 420˙000.00 |
| 4 |
Askion GmbH
Organization address
address: GEWERBEPARK KEPLERSTRASSE 17-19 contact info |
DE (GERA) | participant | 400˙000.00 |
| 5 |
AGROBIOGEN GMBH BIOTECHNOLOGIE
Organization address
address: LAREZHAUSEN 2 contact info |
DE (HILGERTSHAUSEN) | participant | 376˙000.00 |
| 6 |
AIRBUS DEFENCE AND SPACE GMBH
Organization address
address: WILLY MESSERSCHMITT STRASSE 1 contact info |
DE (OTTOBRUNN) | participant | 330˙000.00 |
| 7 |
ROHRER AG WERKZEUG- & MASCHINENBAU
Organization address
address: BREMENSTALLSTRASSE 1 contact info |
CH (MOHLIN) | participant | 295˙400.00 |
| 8 |
INSTITUTUL NATIONAL DE CERCETAREDEZVOLTARE PENTRU MICROTEHNOLOGIE
Organization address
address: Erou iancu Nicolae Street 32B contact info |
RO ("VOLUNTARI, BUCHAREST") | participant | 205˙000.00 |
| 9 |
MEDIZINISCHES VERSORGUNGZENTRUM DRSTEIN + KOLLEGEN LABORATORIUMSMEDIZIN MIKROBIOLOGIE INFEKTIONSEPIDEMIOLOGIE VIROLOGIE TRANSFUSIONSMEDIZIN
Organization address
address: WALLSTRASSE 10 contact info |
DE (MONCHENGLADBACH) | participant | 40˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The objective of PARCIVAL is to develop an integrated and automated multi-analyte lab-on-a-disk platform for the fast and reliable sample in -> answer out diagnosis of highly infectious respiratory pathogens, resistance patterns and biomarkers for individual severity of the infection. The platform format will be based on completely integrated microfluidic foil-disposables. The disposables will feature different panels (selection of pathogens, resistance patterns, biomarkers), which can be freely selected and combined to allow a comprehensive choice of diagnostic parameters by the clinician at the point-of-care, vastly increasing the access to diagnostic information for doctors in everyday situations and emergencies. The integrated platform with pre-packaged liquid and dry reagents will automate all processing steps from sample preparation, over assay processing up to result reporting.
This will allow evidence-based therapeutic decisions, allow antibiotic prescriptions which are tailored to the individual patient and thus offer the prospect to greatly improve therapeutic outcomes. Also, an air-sampling add-on module for monitoring of clinical ventilation systems will be developed and interfaced to the platform. By acting as early warning system that is able to identify airborne pathogens including resistances, this will increase the impact towards the topic 2.3.1-4 (“retard the development of multi-drug resistance”) as well as the area 2.3.1 (“development of effective infection prevention and control strategies”).
The consortium consists of 9 partners (6 enterprises (4 SMEs), 3 institutes). The project is heavily based on the research capabilities of innovative SMEs. Therefore, SMEs will be the main beneficiaries of exploitation in the project. The key-developments of involved European SMEs will support European companies to establish a leading role in the field lab-on-a-chip applications which is based on the huge in vitro diagnostics market.'